scholarly journals P635 Real-world treatment persistence and associated costs with biologic therapy in patients with inflammatory bowel disease (IBD): Results of a retrospective cohort analysis of 1,149 patients treated in Germany

2018 ◽  
Vol 12 (supplement_1) ◽  
pp. S431-S431
Author(s):  
A Groth ◽  
T Wilke ◽  
A Brandes ◽  
B Ratsch ◽  
A Fuchs ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Real World ◽  
Bowel Disease ◽  
Retrospective Cohort ◽  
Biologic Therapy ◽  
Cohort Analysis ◽  
Treatment Persistence ◽  
Retrospective Cohort Analysis ◽  
Inflammatory Bowel

scholarly journals Análise de coorte histórica de 10 anos de ambulatório especializado em doença inflamatória intestinal do Brasil / 10-year retrospective cohort analysis of inflammatory bowel disease in a specialized clinic of Brazil

2021 ◽  
Author(s):  
Jéssica Martins Torres ◽  
Gabriela Santos Silva ◽  
Felipe Bertollo Ferreira ◽  
Ana Paula Hamer Sousa Clara ◽  
Felipe Welling Lorentz ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Retrospective Cohort ◽  
Cohort Analysis ◽  
Epidemiological Data ◽  
Espírito Santo ◽  
Retrospective Cohort Analysis ◽  
Inflammatory Bowel ◽  
Espirito Santo

Introdução: A doença inflamatória intestinal (DII) representa um grupo de afecções crônicas idiopáticas que levam à inflamação do intestino. As duas principais representantesdessa doença são a Doença de Crohn (DC) e a Retocolite Ulcerativa (RCU). A crescente incidência e prevalência das doenças inflamatórias intestinais em países em desenvolvimentocomo o Brasil torna cada vez mais necessário o entendimento do comportamento epidemiológico da doença. Objetivo: Este presente estudo tem como objetivo analisar o perfil clínico epidemiológico da doença inflamatória intestinal em hospital de referência para o tratamento dessa patologia. Métodos: Trata-se de um estudo tipo coorte histórica com abordagem quantitativa, realizado no Ambulatório de Gastroenterologia do Hospital Santa Casa de Misericórdia de Vitória (HSCMV) localizado no estado do Espírito Santo. A população estudada foi adquirida após busca no sistema informatizado dos atendimentos hospitalares e ambulatoriais sob o CID-10 K50 e K51 durante o período de 01/01/2010 até 31/12/2019 (N=300). Resultados: A média de idade no momento do diagnóstico da doença inflamatória intestinal foi de 35,1 anos. A análise comparativa das variáveis epidemiológicas mostra que no grupo de DC 67,5% dos participantes tiveram pelo menos uma internação por exacerbação da doença ao longo de seu acompanhamento, contrastando com 28,9% dos portadores de RCU. Em relação a classe de medicamentos, nota-se que o grupo de RCU teve 24,7% dos participantes usando imunobiológicos durante o período analisado, o uso dessemesmo medicamento no grupo de portadores de DC foi de 63,2%. Conclusão: Este trabalho assume sua importância ao trazer dados novos da epidemiologia da DII no estado do Espírito Santo e do comportamento da doença, além de apresentar diferenças importantes da  literatura mundial, se transformando, assim, em um documento de grande importância para o serviço. Palavras chave: Doença de Crohn, Colite ulcerativa, Epidemiologia AbstractIntroduction: Inflammatory bowel disease it’s an idiopathic disorder that leads to inflammation of the gastroenteric tissue. The two main representatitves of this condition areCrohn’s Disease and Ulcerative Colitis. The increasing incidence of this disorder in developing countries such as Brazil makes the understanding of epidemiological aspects increasingly important. Objective: This article aimed to explore the clinical-epidemiological aspects of patients diagnosed with inflammatory bowel disease. Method: It’s a retrospective cohort study. The study design includes the patients diagnosed with inflammatory bowel disease seen at the gastroenterology clinic of the Hospital Santa Casa de Misericórdia de Vitória during January, 2010 to December 2019. Results: The average age at the time of the diagnosis was 35,1 years old. The analysis shows that 67,5% of the patients with Crohn’s Disease (CD) was hospitalized at least one time due to descompensation compared to 28,9% of Ulcerative Colitis (UC) patients. 24,7% of the UC participants made use of immunobiological therapy contrasted with 63,2% of CD patients. Conclusion: This article brings to light new epidemiological data and disease’s behavior regarding inflammatory bowel disease in the state of Espírito Santo besides uncovers important divergences between this study and other articles. This way, it becomes an important tool to the Gastroenterology clinic.   Keyword: Crohn disease, Colitis ulcerative, Epidemiology

Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy

2019 ◽  
Vol 25 (8) ◽  
pp. 1417-1427 ◽  
Author(s):  
Chao Chen ◽  
Abraham G Hartzema ◽  
Hong Xiao ◽  
Yu-Jung Wei ◽  
Naueen Chaudhry ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Survival Time ◽  
Median Survival ◽  
Real World ◽  
Bowel Disease ◽  
Median Survival Time ◽  
High Rate ◽  
Biologic Treatment ◽  
Treatment Persistence ◽  
Inflammatory Bowel

Abstract Background and aims Medication persistence, defined as the time from drug initiation to discontinuation of therapy, has been suggested as a proxy for real-world therapeutic benefit and safety. This study seeks to compare the persistence of biologic drugs among patients with inflammatory bowel disease (IBD). Methods Patients with newly diagnosed IBD were included in a retrospective study using Truven MarketScan database. Treatment persistence and switching was compared among biologic medications including infliximab, adalimumab, certolizumab, golimumab, and vedolizumab. Predictors for discontinuation and switching were evaluated using time-dependent proportional hazard regression. Results In total, 5612 patients with Crohn’s disease (CD) and 3533 patients with ulcerative colitis (UC) were included in this analysis. Less than half of the patients continued using their initial biologic treatment after 1 year (48.48% in CD cohort; 44.78% in UC cohort). In the first year, adalimumab had the highest persistence and lowest switching rates for both CD (median survival time: 1.04 years) and UC (median survival time: 0.84 years). In subsequent years, infliximab users were more likely to persist in the use of biologic. Combination therapy with immunomodulators significantly decreased the risk of discontinuation, especially when immunomodulator therapy was started more than 30 days before the biologic (hazard ratio [HR], 0.22; CI, 0.16, 0.32). The major predictors for noncompliance included infection and hospitalization. Conclusion Overall, the persistence profiles of biologics suggest a high rate of dissatisfaction or adverse disease outcomes resulting in discontinuation and switching to a different agent. Early initiation of immunomodulators will substantially increase the persistence of biologic treatment.

scholarly journals P406 A retrospective analysis of the efficacy of vedolizumab on extra-intestinal manifestations in patients with inflammatory bowel disease across five European countries

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S412-S414
Author(s):  
U Kopylov ◽  
J Burisch ◽  
S Ben-Horin ◽  
F Braegger ◽  
A Fernández-Nistal ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Real World ◽  
Bowel Disease ◽  
Missing Values ◽  
Disease Duration ◽  
Extraintestinal Manifestations ◽  
Limited Data ◽  
Treatment Persistence ◽  
Inflammatory Bowel

Abstract Background Vedolizumab is an α4β7 integrin monoclonal antibody indicated for moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC). There are limited data on how vedolizumab impacts extraintestinal manifestations (EIM) in inflammatory bowel disease (IBD). The aim of the study was to analyse the effect of vedolizumab on EIM in a real-world cohort of IBD patients. Methods A multicentre retrospective study was conducted in Belgium, Denmark, Israel, the Netherlands and Switzerland. Adult patients with moderately to severely active IBD and concurrent active EIM with at least 6 months follow-up after vedolizumab initiation (index date) were enrolled. Improvement of EIM was defined as absence of symptoms (resolution) or partial response (reduction of symptoms). Results 99 patients were included (UC: 44, CD: 55); the majority of active EIM at index were musculoskeletal (Table 1). Median disease duration at index was 9 (IQR: 3-19) years and 77% of patients had been exposed to 1+ biologic. Overall, after 6 and 12 months of vedolizumab, 37% and 50% of EIM respectively were reported as improved, 22%, 25% as stable (no change) and 1% and 3% as worsened (Table 2), missing values were 5% and 4%, respectively. Median time since first EIM improvement was 0.5 months (Figure 1). At 6 and 12 months, 48% (10/21) and 33% (6/18) of patients experienced clinical response/remission of their IBD, respectively. Vedolizumab treatment persistence at 12 months was 83% overall (Figure 2). Adverse Events were reported for 18% patients; 96% of them non-serious. Conclusion Vedolizumab treatment was associated with an improvement in 37% and 50% of EIM at 6 and 12 months, respectively, in a real-world IBD cohort.

Sign in / Sign up

Export Citation Format

Share Document